Anna Jeter

Position: CDO & Co-Founder

Anna is an innovator and a dynamic business leader with a passion for advancing healthcare through world-class diagnostics.​ As the Chief Development Officer of AOA, she is pioneering the development of the groundbreaking GlycoLocateTM platform for early cancer detection by utilizing tumor marker gangliosides and AI to solve some of the most difficult challenges in diagnostics today.

Anna was named to Inc. Magazine’s 2022 Female Founders 100 List. She brings a wealth of experience to AOA having overseen the inclusion of multiple products into national and pan-European guidelines, and she has experience with US FDA submissions for 510(k), PMA, and CLIA LTD regulatory routes.​

Anna has a unique global perspective on healthcare having led teams launching paradigm changing diagnostics in women’s health in Europe, the Middle East, Latin America and Asia.